asunaprevir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
Hepatitis Virus C (HVC) protease inhibitors	4889	630420-16-5

Description:

Molecule

Description

Molfile Inchi Smiles

Synonyms:

asunaprevir
BMS-650032
sunvepra

an NS3 protease inhibitor against hepatitis C virus

Molecular weight: 748.29
Formula: C35H46ClN5O9S
CLOGP: 5.67
LIPINSKI: 3
HAC: 14
HDO: 3
TPSA: 182.33
ALOGS: -5.40
ROTB: 13

Drug dosage:

Dose	Unit	Route
0.20	g	O

ADMET properties:

Property	Value	Reference
Vd (Volume of distribution)	2.77 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	11.78 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.01 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	20 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
July 4, 2014	PMDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Alanine aminotransferase increased	78.31	52.11	30	495	103740	63384757
Liver injury	66.03	52.11	23	502	60497	63428000

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Alanine aminotransferase increased	83.81	46.83	39	838	162531	79580980
Hepatocellular carcinoma	75.90	46.83	18	859	9003	79734508
Hepatic function abnormal	65.55	46.83	26	851	73081	79670430
Pyrexia	57.56	46.83	52	825	678657	79064854
Ascites	54.49	46.83	23	854	75539	79667972
Hepatitis B DNA increased	53.26	46.83	9	868	806	79742705
Renal impairment	49.21	46.83	27	850	157756	79585755
Liver disorder	48.75	46.83	21	856	72396	79671115

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J05AP06	ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Antivirals for treatment of HCV infections
ATC	J05AP58	ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Antivirals for treatment of HCV infections
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D011480	Protease Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Chronic hepatitis C	indication	128302006

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	4.1	acidic
pKa2	1.15	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Genome polyprotein	Polyprotein		POLG_HCVH	INHIBITOR	Ki	9.40		SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE
NS3	Enzyme		A3EZI9_9HEPC		EC50	8.92		CHEMBL
Genome polyprotein	Unclassified		A3EZJ3_9HEPC		EC50	8.92		CHEMBL

External reference:

ID	Source
S9X0KRJ00S	UNII
D10093	KEGG_DRUG
C3491974	UMLSCUI
CHEBI:134723	CHEBI
2R9	PDB_CHEM_ID
CHEMBL2105735	ChEMBL_ID
16076883	PUBCHEM_CID
DB11586	DRUGBANK_ID
9472	INN_ID
C571889	MESH_SUPPLEMENTAL_RECORD_UI
10882	IUPHAR_LIGAND_ID
1652103	RXNORM
016060	NDDF
715390003	SNOMEDCT_US

Pharmaceutical products:

None